Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial-Reference-Cited by-同舟云学术

Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial

Published:2015-05-03 Issue:7 Volume:90 Page:634-638
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Calvaruso Giuseppina¹,Vitrano Angela¹,Di Maggio Rosario¹,Lai Eliana²,Colletta Grazia³,Quota Alessandra⁴,Gerardi Calogera⁵,Rigoli Luciana Concetta⁶,Sacco Massimiliano¹,Pitrolo Lorella¹,Maggio Aurelio¹

Affiliation:

1. A.O.R. “Villa Sofia - V; Cervello’’; Unità Operativa Complessa Ematologia II; Palermo Italy

2. Dipartimento Di Scienze Mediche; Sezione Talassemici Adulti, University of Cagliari; Italy

3. Azienda Ospedaliera Univiversità Policlinico “Vittorio Emanuele -P.O Ferrarotto”; Catania Italy

4. A.O. ‘‘V; Emanuele III’’; Centro Microcitemia; Gela (CL) Italy

5. A.O.O.C.R.; U.O.S. Di Talassemia; Sciacca Italy

6. U.O; Genetica Ed Immunologia Pediatrica; Policlinico “G. Martino”; Messina Italy

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.24024/fullpdf

Reference20 articles.

1. The β-thalassemias;Olivieri;N Engl J Med,1999

2. Elevated liver iron concentration is a marker of increased morbidity in patients with beta thalas- semia intermedia;Musallam;Haematologica,2011

3. Viprakasit V Lee-Lee C Chong QT Iron chelation therapy in the management of thalassemia: The Asian perspectives Int J Hematol 2009 90 435 445

4. Adherence to deferoxamine therapy: Heeding hippocrates and osler;Olivieri;Am J Hematol,2004

5. Taher AT Porter JB Viprakasit V Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-Year results from a prospective, randomized, double-blind, placebo-controlled study Blood 2012 120 970 977

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs;International Journal of Molecular Sciences;2023-11-25

2. How I treat non-transfusion-dependent β-thalassemia;Blood;2023-09-14

3. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia;Cochrane Database of Systematic Reviews;2023-03-06

4. The metal ion hypothesis of Alzheimer’s disease and the anti-neuroinflammatory effect of metal chelators;Bioorganic Chemistry;2023-02

5. Ferroptosis As a Mechanism for Health Effects of Essential Trace Elements and Potentially Toxic Trace Elements;Biological Trace Element Research;2022-12-28